pharmaceuticals

pharmaceuticals Articles

Raptor Pharmaceuticals saw its shares sink on Monday after it announced its first commercial sale of Quinsair in Germany and Denmark.
Viamet Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Insys Therapeutics watched its stock slide early Monday morning following the release of less-than-favorable revenue estimates.
Over the past week, Valeant Pharmaceuticals and a few other biotech companies made impressive runs.
Depomed saw its stock surge early Friday morning following news of an open letter from activist firm Starboard Value.
If the momentum in biotech can continue, then companies with catalysts within the next 12 to 18 months could get an added boost with any good news.
Ionis Pharmaceuticals made waves in the market on Thursday following a business update on its IONIS-TTR program.
This week's top U.S. growth calls from the analysts at Jefferies focus on companies that have some outstanding upside potential, including the following three leading biotech stocks.
At the end of March, a district court granted the request from Depomed and lifted the stay of its patent infringement suit against Purdue.
Not only does Aldeyra Therapeutics have a good cash position, but it also it has a strong pipeline as well. One key analyst has decided to weigh in on the firm and where it stands to go from here.
Over the past week, Opko Health, Acadia Pharmaceuticals and a few other biotech companies made impressive runs.
Akari Therapeutics has announced preliminary results from the first paroxysmal nocturnal hemoglobinuria patient treated with subcutaneously administered Coversin.
Regeneron Pharmaceuticals has announced that two Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis met their...
Genocea Biosciences soared early on Thursday, following the release of positive data from its mid-stage genital herpes clinical trial.
Opko Health saw its shares slide in Wednesday’s regular trading session following the release of a complete response letter from the FDA.